Commits KRW450tn over 5 Years
Samsung Group announced on May 24 an expansion of its investment commitment with plans to spend a total of 450 trillion won over five years until 2026, to accelerate growth in semiconductors, biopharmaceuticals and other next-generation technologies.
With the investment, which represents a more than 30 percent increase from the 330 trillion won spent in the previous five-year period, Samsung expects to drive long-term growth in strategic businesses and to help strengthen the global industrial ecosystem of crucial technology and innovation. The investment includes capital expenditures and R&D spending, and 360 trillion won out of the total will be invested in Korea.
A number of Samsung-affiliated companies, including Samsung Electronics and Samsung Biologics, will lead the investment in their respective business areas.
In semiconductors, Samsung Electronics plans to continue investing in memory chips to solidify its global leadership and strengthen research of new materials and chip architectures to make continuous advancements on process technologies.
Samsung's investment will also focus on enhancing competitiveness in fabless semiconductors, namely in the areas of high-performance, low-power application processors, next-generation telecommunication chips and high-resolution image sensors.
In the foundry business, Samsung will lead the development of the industry’s most advanced process technology and bring forward the mass production of chips based on the 3-nanometer process. Samsung also continues to develop new integrated semiconductor solutions that combine processing and memory functions onto a single chip.
Samsung will continue to make investments in technologies to support emerging applications and new innovative businesses. In artificial intelligence, Samsung is strengthening its research leadership through its global network of R&D centers and collaboration programs with academia.
For telecommunications, Samsung will leverage its expertise from leading the early 5G commercialization to spearhead technology development and standard-setting for next-generation 6G communications technology.
In biopharmaceuticals, Samsung Biologics and Samsung Bioepis will continue to invest aggressively in expanding the contract manufacturing capacity and broadening the biosimilar product pipeline.
Along with the investment commitment, Samsung will step up its job creation drive and plans to generate 80,000 new jobs through 2026, or about 16,000 positions annually, outpacing the previous goal of creating 40,000 jobs between 2021 and 2023. The new jobs will be created primarily in core businesses, including semiconductors and biopharmaceuticals.
Samsung will also continue to expand its software training initiative for the youth and provide educational opportunities for students through programs such as Samsung Software Academy For Youth and Samsung Dream Class.
Separately, Samsung plans to increase support programs for small- and mid-sized companies and venture firms to achieve sustainable growth for the overall ecosystem. This includes continuing to provide the “Smart Factory” program, an initiative that helps small and medium enterprises to enhance their manufacturing capabilities, increasing incentive payments, and backing more startup companies through Samsung’s venture incubation platform, C-Lab.